Anlon Healthcare has incorporated a new subsidiary, Anlon Biologics Private Limited, effective July 10, 2026, to manufacture peptides, biosimilars, and biological compositions. This strategic move is intended to leverage growth opportunities in the biologics sector and complement the company's existing business in the pain management segment. The incorporation was communicated pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The newly incorporated entity operates within the pharmaceuticals industry and has been established with an authorized share capital of Rs. 1,000,000 and a paid-up share capital of Rs. 1,000,000. As the subsidiary is recently formed, it currently reports nil turnover and has not yet commenced business operations.

Anlon Healthcare has subscribed to 65% of the share capital of the subsidiary. The subscription was made via cash and banking channels for an aggregate consideration of Rs. 650,000. This investment comprises 65,000 equity shares with a face value of Rs. 10 each.

Details of the Subsidiary

The following table outlines the key financial and structural details of the newly incorporated entity:

The management stated that the incorporation aligns with the company's long-term growth objectives, positioning it to benefit from expanding opportunities in the peptides and biosimilars segment. Punitkumar Rasadia, Managing Director of Anlon Healthcare Limited, signed the regulatory filing confirming the details.

Anlon Healthcare Limited disclosed that its Chairman & Managing Director, Mr. Punitkumar Rasadia, participated in an interview with Sumit Mehrotra, former Senior Anchor @cnbcawaaz, on July 06, 2026. The interaction aimed to provide stakeholders with insights into the company's current business performance and future outlook without disclosing any unpublished price sensitive information (UPSI).

During the interview, Mr. Rasadia provided a comprehensive overview of the company's business performance and the prevailing industry outlook. He elaborated on the current market conditions and shared recent operational updates, highlighting the company's adaptability to the dynamic healthcare sector.

The discussion also focused on the company's growth strategy and future plans. Mr. Rasadia outlined the roadmap for expansion, including potential capital expenditure and capacity expansion initiatives. He addressed topics concerning acquisition and disinvestment strategies, indicating the management's proactive approach to scaling operations.

Financial performance guidance was a key component of the interview, offering shareholders a perspective on the company's fiscal expectations. The management emphasized that all information shared during the session was already available in the public domain, ensuring compliance with regulatory standards.

The interview is accessible for viewing on YouTube, Facebook, Instagram, X, and LinkedIn. The company confirmed that the interaction was conducted in adherence to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.